Clinical trial · Observational
High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome (PCOS)
High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome
NCT01463969CI-TRIAL-00005711completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the present study, serum pentraxin 3 level and its relationship with insulin resistance were determined in patients with Polycystic Ovary Syndrome (PCOS. It was found that PTX3 level is increased in patients with PCOS and it is positively correlated with HOMA-IR.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- PCOS patients
- label
- Control group
Primary outcomes (1)
- measure
- Level of of pentraxin3 in cases with Polycystic Ovarian Syndrome
- timeFrame
- 1 year
- description
- Mean PTX3 was significantly higher in patients with PCOS. This means that there is increased level of inflamation in patients with PCOS.
Secondary outcomes (1)
- measure
- Relationship of PTX3 with insuline resistance in patients with PCOS.
- timeFrame
- 1 year
- description
- PTX3 was positively correlated with HOMA-IR. This means that inflamation may cause insuline resistance in patients with PCOS.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Absence of significant abnormalities on physical examination except hirsutism * No lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy * Normal thyroid function and prolactin level * Absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic disease Exclusion Criteria: * Pregnant * Possible ovarian tumors, * Congenital adrenal hyperplasia or * BMI greater than 35 kg/m2
References
Publications (0)
Data not yet available
No reference posted for this study.